Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1991

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Postponement of withdrawal bleeding with a monophasic oral contraceptive

containing desogestrel and ethinylestradiol.

AUTHORS

de Voogd WS

SOURCE

CONTRACEPTION. 1991 Aug;44(2):107-12.

ABSTRACT

This study investigated the ability of a monophasic sub-50 oral contraceptive (OC) containing desogestrel and ethinyl

estradiol to postpone withdrawal bleeding in normal health women. In the analyzed group of 105 regular users of

Marvelon, about 75% did not experience any vaginal bleeding during the 21 days of postponement. A 95%

confidence interval was calculated which suggests that the % of women able to postpone their withdrawal bleeding

successfully for 19 days ranges between 67.0% and 83.5%. Women with no vaginal blood loss in the postponement

period were some willing to try this method of postponement again, compared to women who experienced vaginal

blood loss in the postponement period. This difference was statistically significant. Nevertheless, the majority of

women with vaginal blood loss were also willing to try this method again if necessary. This study suggests that

Marvelon offers an effective and acceptable method of postponing withdrawal bleeding for 3 weeks for most regular

users of this OC. (author's) (PubHealth.info Document ID: CONT3T 2013-06)

PubHealth.info NOTE: The author(s) of this article titled, "Postponement of withdrawal bleeding with a monophasic

oral contraceptive containing desogestrel and ethinylestradiol.", is(are) de Voogd WS. The source of this article is

"CONTRACEPTION. 1991 Aug;44(2):107-12.". This article was published in 1991 in English language(s).

(PubHealth.info® Document ID: CONT3T 2013-06. All rights reserved with PubHealth.info) PIN: 12013

This article is peer-reviewed.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.